Cannabidiol oil stocks list 10 cbd oil stocks to watch right now

2018-09-05 09:19:07 top cbd oil stocks right now cannabidiol market forecast cannabidiol oil stocks list cannabis derivatives cannabidiol market size cbd oil stocks 2018 cbd market analysis Cannabidiol stocks are poised for solid growth in the coming years, with new hemp-derived medicines and other products hitting the markets. We take a look at 10 of the best CBD oil stocks available now.

CBD is not yet recognized by the U.S. Food & Drug Administration (FDA) as a medically beneficial compound, but scientific studies (many sponsored by the U.S. government) show that it could be used to treat a wide range of conditions, including arthritis, insomnia, anxiety, chronic pain, and epilepsy. (Source: “ Cannabidiol (CBD) — what we know and what we don’t,” Harvard Medical School, August 24, 2018.)


“In terms of the CBD market size, I estimate an almost $3 billion market by 2021. Right now there are 15 states that allow CBD only — this is in addition to the 28 states plus DC that have legalized medical marijuana,” said Matt Karnes of Greenwave Advisors LLC. (Source: “ The Cannabis Market That Could Grow 700% By 2020,” Forbes, December 12, 2016.)

According to a 2018 report, the demand for CBD used for chronic pain is expected to help fuel the medical cannabis market. The medical cannabis market is projected to grow from $7.0 billion in 2017 to over $55.0 billion by 2024. (Source: “ CBD Demand for Chronic Pain Treatment is Set to Grow the Medical Cannabis Market,” Cision, September 4, 2018.)

The laws in the United Kingdom (England, Wales, Scotland, and Northern Ireland) governing marijuana are very strict. Nevertheless, the U.K’s Advisory Council on the Misuse of Drugs has recommended that cannabis-derived medical products be available by prescription. (Source: “ Cannabis-derived medicinal products recommended to be available on prescription,” GOV.UK, July 24, 2018.)

CBD is not yet recognized by the U.S. Food & Drug Administration (FDA) as a medically beneficial compound, but scientific studies (many sponsored by the U.S. government) show that it could be used to treat a wide range of conditions, including arthritis, insomnia, anxiety, chronic pain, and epilepsy. (Source: “ Cannabidiol (CBD) — what we know and what we don’t,” Harvard Medical School, August 24, 2018.)

“In terms of the CBD market size, I estimate an almost $3 billion market by 2021. Right now there are 15 states that allow CBD only — this is in addition to the 28 states plus DC that have legalized medical marijuana,” said Matt Karnes of Greenwave Advisors LLC. (Source: “ The Cannabis Market That Could Grow 700% By 2020,” Forbes, December 12, 2016.)

According to a 2018 report, the demand for CBD used for chronic pain is expected to help fuel the medical cannabis market. The medical cannabis market is projected to grow from $7.0 billion in 2017 to over $55.0 billion by 2024. (Source: “ CBD Demand for Chronic Pain Treatment is Set to Grow the Medical Cannabis Market,” Cision, September 4, 2018.)

The laws in the United Kingdom (England, Wales, Scotland, and Northern Ireland) governing marijuana are very strict. Nevertheless, the U.K’s Advisory Council on the Misuse of Drugs has recommended that cannabis-derived medical products be available by prescription. (Source: “ Cannabis-derived medicinal products recommended to be available on prescription,” GOV.UK, July 24, 2018.)

Dear Reader: There is no magic formula to getting rich. Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis. We are 100% independent in that we are not affiliated with any bank or brokerage house. Information contained herein, while believed to be correct, is not guaranteed as accurate. Warning: Investing often involves high risks and you can lose a lot of money. Please do not invest with money you cannot afford to lose. The opinions in this content are just that, opinions of the authors. We are a publishing company and the opinions, comments, stories, reports, advertisements and articles we publish are for informational and educational purposes only; nothing herein should be considered personalized investment advice. Before you make any investment, check with your investment professional (advisor). We urge our readers to review the financial statements and prospectus of any company they are interested in. We are not responsible for any damages or losses arising from the use of any information herein. Past performance is not a guarantee of future results. All registered trademarks are the property of their respective owners.